Personal profile
Biography
Dr. Sheng Yu Ang is a research fellow within the Servier Drug Discovery Program at MIPS. He uses his expertise in GPCR pharmacology and receptor signal transduction to facilitate drug discovery efforts across multiple therapeutic areas. His current research focuses on discovery of novel drug candidates for the treatment of CNS disorders.
Research area keywords
- Drug Discovery
- Pharmacology
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Collaborations and top research areas from the last five years
Projects
- 2 Finished
-
Potent and selective nonhallucinogenic serotonin 2A receptor agonists for the treatment of severe mental health disorders
Ang, S. Y. (Primary Chief Investigator (PCI))
1/01/25 → 31/12/25
Project: Research
-
Discovery of Novel GPR17 Modulators for Multiple Sclerosis
Ang, S. Y. (Primary Chief Investigator (PCI)) & De la Fuente Gonzalez, R. (Associate Investigator (AI))
1/01/25 → 31/12/25
Project: Research
Research output
- 11 Article
-
GPR55 regulates the responsiveness to, but does not dimerise with, α1A-adrenoceptors
Walsh, S. K., Lipina, C., Ang, S. Y., Sato, M., Chia, L. Y., Kocan, M., Hutchinson, D. S., Summers, R. J. & Wainwright, C. L., Jun 2021, In: Biochemical Pharmacology. 188, 12 p., 114560.Research output: Contribution to journal › Article › Research › peer-review
1 Link opens in a new tab Citation (Scopus) -
Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists
Zhang, X., Belousoff, M. J., Zhao, P., Kooistra, A. J., Truong, T. T., Ang, S. Y., Underwood, C. R., Egebjerg, T., Šenel, P., Stewart, G. D., Liang, Y.-L., Glukhova, A., Venugopal, H., Christopoulos, A., Furness, S. G. B., Miller, L. J., Reedtz-Runge, S., Langmead, C. J., Gloriam, D. E. & Danev, R. & 2 others, , 5 Nov 2020, In: Molecular Cell. 80, 3, p. 485-500 16 p.Research output: Contribution to journal › Article › Research › peer-review
163 Link opens in a new tab Citations (Scopus) -
INSL5 activates multiple signalling pathways and regulates GLP-1 secretion in NCI-H716 cells
Ang, S. Y., Evans, B. A., Poole, D. P., Bron, R., DiCello, J. J., Bathgate, R. A. D., Kocan, M., Hutchinson, D. S. & Summers, R. J., 1 Apr 2018, In: Journal of Molecular Endocrinology. 60, 3, p. 213-224 12 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile18 Link opens in a new tab Citations (Scopus) -
ML290 is a biased allosteric agonist at the relaxin receptor RXFP1
Kocan, M., Sarwar, M., Ang, S. Y., Xiao, J., Marugan, J., Hossain, M. A., Wang, C., Hutchinson, D. S., Samuel, C. S., Agoulnik, A. I., Bathgate, R. A. D. & Summers, R. J., 1 Dec 2017, In: Scientific Reports. 7, 1, 14 p., 2968.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile58 Link opens in a new tab Citations (Scopus) -
Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor
Ang, S. Y., Hutchinson, D. S., Patil, N., Evans, B. A., Bathgate, R. A. D., Halls, M. L., Hossain, M. A., Summers, R. J. & Kocan, M., 1 May 2017, In: British Journal of Pharmacology. 174, 10, p. 1077-1089 13 p.Research output: Contribution to journal › Article › Research › peer-review
32 Link opens in a new tab Citations (Scopus)